XML 43 R35.htm IDEA: XBRL DOCUMENT v3.24.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

Segment information for the three and nine months ended September 30, 2024 and 2023 is as follows (in thousands):

		Three Months Ended September 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	25,488			$	—			$	—			$	25,488
Cost of revenues			958				—				—				958
Gross profit			24,530				—				—				24,530
Operating expenses excluding cost of revenues:
Selling and marketing			13,699				—				—				13,699
Research and development			2,553				222				—				2,775
General and administrative			2,225				1,593				5				3,823
Total operating expenses excluding cost of revenues			18,477				1,815				5				20,297
Income (loss) from operations		$	6,053			$	(1,815	)		$	(5	)		$	4,233
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—			$	237			$	—			$	237
Stock-based compensation total		$	—			$	237			$	—			$	237

		Nine Months Ended September 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	77,885			$	—			$	—			$	77,885
Cost of revenues			2,707				—				—				2,707
Gross profit			75,178				—				—				75,178
Operating expenses excluding cost of revenues:
Selling and marketing			40,655				—				—				40,655
Research and development			7,639				673				—				8,312
General and administrative			7,031				3,608				6				10,645
Total operating expenses excluding cost of revenues			55,325				4,281				6				59,612
Income (loss) from operations		$	19,853			$	(4,281	)		$	(6	)		$	15,566
Supplemental disclosure of stock-based compensation expense:
General and administrative		$	—			$	264			$	—			$	264
Stock-based compensation total		$	—			$	264			$	—			$	264

		Three Months Ended September 30, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	32,042			$	—			$	—			$	32,042
Cost of revenues			1,184				—				—				1,184
Gross profit			30,858				—				—				30,858
Operating expenses excluding cost of revenues:
Selling and marketing			13,928				—				—				13,928
Research and development			3,009				—				—				3,009
General and administrative			1,159				—				(2	)			1,157
Total operating expenses excluding cost of revenues			18,096				—				(2	)			18,094
Income from operations		$	12,762			$	—			$	2			$	12,764
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation total		$	—			$	—			$	—			$	—

		Nine Months Ended September 30, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Revenues		$	86,302			$	—			$	—			$	86,302
Cost of revenues			3,386				—				—				3,386
Gross profit			82,916				—				—				82,916
Operating expenses excluding cost of revenues:
Selling and marketing			44,695				—				—				44,695
Research and development			9,212				—				—				9,212
General and administrative			4,055				—				552				4,607
Total operating expenses excluding cost of revenues			57,962				—				552				58,514
Income (loss) from operations		$	24,954			$	—			$	(552	)		$	24,402
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation total		$	—			$	—			$	—			$	—

The table below presents total assets as of September 30, 2024 and December 31, 2023.

		September 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	113,682			$	10,646			$	912			$	125,240

		December 31, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Total assets		$	101,761			$	13,865			$	913			$	116,539

The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.

		Nine Months Ended September 30, 2024
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	2,366			$	14			$	—			$	2,380

		Nine Months Ended September 30, 2023
		Gyre Pharmaceuticals				Gyre				Other				Consolidated
Purchase of property and equipment		$	6,193			$	—			$	—			$	6,193

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration